Longeveron Inc. (LGVN) Bundle
A Brief History of Longeveron Inc. (LGVN)
Founding and Early Years
Longeveron Inc. was founded in 2014 and is headquartered in Miami, Florida. The company was established to develop cellular therapies for aging-associated conditions and other serious unmet medical needs. Its primary focus is on leveraging the therapeutic potential of mesenchymal stem cells (MSCs) derived from bone marrow.
Initial Public Offering
In December 2020, Longeveron went public through an initial public offering (IPO), raising approximately $28 million by offering 2.8 million shares at a price of $10 per share. The stock began trading on the NASDAQ under the ticker symbol LGVN.
Clinical Trials and Developments
Longeveron has been actively conducting clinical trials for its lead product candidate, Lomecel-B, aimed at treating aging frailty and other conditions. As of October 2023, the company is in Phase 2b trials for aging frailty, with a reported enrollment of 150 patients.
Financial Performance
For the fiscal year 2022, Longeveron reported revenue of $1.5 million, primarily from its clinical trials and partnerships.
As of the end of Q2 2023, the company had cash and cash equivalents of approximately $34 million, enabling it to fund ongoing clinical programs.
| Year | Revenue ($ million) | Net Income ($ million) | Cash Position ($ million) |
|---|---|---|---|
| 2020 | 0.5 | -12.3 | 28.0 |
| 2021 | 1.0 | -11.8 | 25.0 |
| 2022 | 1.5 | -10.5 | 30.0 |
| 2023 Q2 | 0.8 | -5.0 | 34.0 |
Partnerships and Collaborations
Longeveron has established collaborations with various academic institutions and pharmaceutical companies to enhance its research capabilities. Notably, the company partnered with the University of Miami to advance its MSC research.
Market Position and Future Outlook
As of September 2023, Longeveron holds a market capitalization of approximately $150 million. The interest in cellular therapies, particularly for age-related conditions, positions the company in a growing sector of the biotechnology industry.
A Who Owns Longeveron Inc. (LGVN)
Ownership Structure
Longeveron Inc. (LGVN) operates with a diverse ownership structure consisting of institutional investors, individual shareholders, and company insiders. As of the latest report, the following breakdown highlights major stakeholders:
| Owner Type | Percentage Ownership | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 55% | 7,300,000 shares |
| Insiders | 15% | 2,000,000 shares |
| Retail Investors | 30% | 4,500,000 shares |
Significant Institutional Investors
Within the institutional ownership category, several prominent investment firms hold notable stakes in Longeveron Inc. The following table outlines key institutional investors and their respective holdings:
| Institution | Number of Shares | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 2,000,000 | 15% |
| The Vanguard Group, Inc. | 1,500,000 | 11% |
| State Street Corporation | 1,000,000 | 8% |
| Invesco Ltd. | 500,000 | 4% |
Insider Ownership
Insider ownership plays a crucial role in Longeveron Inc.'s governance. The table below lists key executives and board members along with their respective shareholdings:
| Name | Title | Shares Owned |
|---|---|---|
| W. Thomas McCarthy | CEO | 900,000 |
| Marcia A. K. V. Koenig | COO | 500,000 |
| Rick G. McDonald | Board Member | 300,000 |
| Linda S. Thornton | Board Member | 300,000 |
Recent Financial Performance
Longeveron Inc. reported its financial performance for the fiscal year 2022, which showcases its economic standing and shareholder value:
| Financial Metric | Amount (in USD) |
|---|---|
| Revenue | $12 million |
| Net Income | ($3 million) |
| Total Assets | $25 million |
| Total Liabilities | $10 million |
Market Performance
The stock performance of Longeveron Inc. (LGVN) over the past year has been noteworthy, reflecting the market's response to its operational strategies:
| Metric | Value |
|---|---|
| Current Share Price | $2.50 |
| 52-Week High | $5.50 |
| 52-Week Low | $1.80 |
| Market Capitalization | $50 million |
Longeveron Inc. (LGVN) Mission Statement
Company Overview
Longeveron Inc. (Ticker: LGVN) is a biotechnology company focused on developing and commercializing cellular therapies for chronic and aging-related diseases. The mission of Longeveron is to improve health and quality of life for patients by harnessing the power of regenerative medicine.
Mission Statement
The mission of Longeveron is to lead the advancement of cellular therapies that restore health and function to patients with serious diseases, particularly in the realm of aging-related conditions. The company aims to leverage its proprietary products to create transformative therapies that can positively impact lives globally.
Core Values
- Innovation: Commitment to advancing scientific research and technology in regenerative medicine.
- Integrity: Upholding the highest standards of ethics and transparency in all operations.
- Patient-Centered: Focusing on the needs and safety of patients as the priority in development and clinical trials.
- Collaboration: Engaging with healthcare professionals, researchers, and partners to accelerate breakthroughs.
Financial Overview
As of September 2023, Longeveron Inc. reported the following financial data:
| Metric | Value |
|---|---|
| Market Capitalization | $40.25 million |
| Total Revenue (2022) | $2.8 million |
| Net Loss (Q2 2023) | ($9.5 million) |
| Cash and Cash Equivalents (Q2 2023) | $12.3 million |
| Research and Development Expenses (2022) | $10.2 million |
| Clinical Trials in Process | 3 |
Strategic Goals
- Expand the clinical development of Lomecel-B, a treatment for aging-related conditions.
- Enhance partnerships with academic institutions to foster research and development.
- Achieve regulatory approvals for expanded indications of cellular therapies.
- Increase operational efficiencies to manage costs effectively.
Recent Developments
In 2023, Longeveron completed a Phase 2 clinical trial for Lomecel-B in patients with Alzheimer’s disease, which showed promising results. The company is currently preparing for a potential Phase 3 trial.
Future Outlook
Looking forward, Longeveron aims to solidify its position as a leader in regenerative medicine. The company has set a target to achieve profitability by late 2024 and to expand its market share in the therapeutic areas of cardiovascular and neurodegenerative diseases.
How Longeveron Inc. (LGVN) Works
Company Overview
Company Overview
Longeveron Inc. (LGVN) is a clinical-stage biotechnology company specializing in the development of innovative cell therapies for aging-related conditions and other serious diseases. As of October 2023, the company is focused on leveraging its proprietary cell therapy platform to address unmet medical needs.
Business Model
The business model of Longeveron revolves around the development and commercialization of cell therapies, primarily based on its Allogeneic Mesenchymal Stem Cells (MSCs). These therapies are intended for various therapeutic uses, including:
- Cardiovascular diseases
- Neurological disorders
- Aging-related conditions
Clinical Trials
Longeveron is actively conducting clinical trials to evaluate the efficacy and safety of its products. As of October 2023, the following trials are ongoing:
| Trial Name | Indication | Phase | Estimated Completion Date |
|---|---|---|---|
| ALCAPS | Alzheimer's Disease | Phase 2b | Q4 2024 |
| MI-CP | Myocardial Infarction | Phase 2 | Q3 2025 |
| ADAPT | Age-Related Frailty | Phase 2 | Q1 2025 |
Financial Performance
As of the latest financial report for Q2 2023, Longeveron reported the following financial data:
| Financial Metric | Q2 2023 | Q1 2023 | Year-over-Year Change (%) |
|---|---|---|---|
| Total Revenue | $1.2 million | $0.9 million | 33.3% |
| Net Loss | ($3.5 million) | ($3.8 million) | 7.9% |
| Cash and Cash Equivalents | $15 million | $18 million | -16.7% |
Market Potential
The market potential for Longeveron's therapies is significant. According to market research, the global cell therapy market is projected to reach:
| Year | Market Size (USD Billion) |
|---|---|
| 2023 | $5.18 billion |
| 2025 | $8.02 billion |
| 2030 | $25.45 billion |
Partnerships and Collaborations
Longeveron has established strategic partnerships to enhance its research and development capabilities. Significant collaborations include:
- University of Miami – Research on MSCs
- US Military – Developing therapies for combat-related trauma
- Various clinical research organizations for trial management
Regulatory Environment
Longeveron operates under the rigorous regulatory standards set by the U.S. Food and Drug Administration (FDA). As of October 2023, they have received:
- Fast Track Designation for Alzheimer’s trials
- Orphan Drug Designation for certain conditions
Future Outlook
Looking ahead, Longeveron aims to advance its clinical trials while exploring additional indications for its cell therapies. This strategic direction is expected to enhance its market presence and attract potential investors.
How Longeveron Inc. (LGVN) Makes Money
Revenue Sources
Longeveron Inc. primarily generates revenue through its development of regenerative medicine therapies, focusing on cell therapy products. The company develops medicinal products derived from mesenchymal stem cells (MSCs).
Partnerships and Collaborations
The company collaborates with various research institutions and pharmaceutical companies, which can lead to joint ventures, funding opportunities, and revenue from shared research initiatives.
Clinical Trials
Longeveron is actively involved in clinical trials. The funding for these trials sometimes comes from government grants, private investors, or partnerships. In 2022, Longeveron reported a total expenditure of approximately $14 million on R&D activities.
Product Pipeline
The company has several products in its pipeline. As of 2023, their lead product, Lomecel-B, is in Phase 2 clinical trials for multiple indications, including aging-related frailty and COVID-19 related acute respiratory distress syndrome (ARDS). The commercialization of these therapies is expected to generate substantial revenue.
Financial Performance
According to the financial report for Q2 2023, Longeveron had total assets of approximately $37 million, with cash and cash equivalents around $25 million.
Market Potential
The global regenerative medicine market size was valued at approximately $27 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of over 25% from 2023 to 2030. This market potential provides Longeveron with a significant opportunity for growth.
Revenue Projections
The management has projected that, if successful in their ongoing trials and subsequent product launches, Longeveron could achieve revenues ranging from $100 million to $500 million by 2025.
Investment and Funding
As of the latest funding round, Longeveron has raised approximately $30 million through equity offerings and government grants. This funding supports ongoing research and development efforts.
| Year | R&D Expenditure | Total Assets | Cash and Cash Equivalents | Revenue Projections |
|---|---|---|---|---|
| 2022 | $14 million | $30 million | $20 million | N/A |
| 2023 | N/A | $37 million | $25 million | $100 million - $500 million |
Regulatory Milestones
Achieving regulatory approvals for new therapies can also lead to considerable financial gains through product licensing and sales. The company is in discussions with the FDA regarding its approval pathways.
Longeveron Inc. (LGVN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support